LIV 2008
Alternative Names: Humanized anti-TROP-2 antibody - Chiome Bioscience; LIV-2008; LIV-2008/2008b; LIV-2008bLatest Information Update: 28 Oct 2024
At a glance
- Originator LivTech
- Developer Chiome Bioscience
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action TROP2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for preclinical development in Cancer in Japan (Parenteral)
- 10 Oct 2022 LIV 2008 is still in preclinical trials for Cancer in Japan (Chiome Bioscience pipeline, October 2022)
- 28 Jun 2021 No recent reports of development identified for preclinical development in Cancer in Japan (Parenteral)